Hand-out
Press Releases
Apnimed to Host Virtual Investor Event Highlighting the Potential for AD109 as a Novel Pharmacotherapy for Obstructive Sleep Apnea on April 11, 2025
CAMBRIDGE, Mass., March 25, 2025 /PRNewswire/ -- Apnimed, Inc., a pharmaceutical company focused on discovery, development, and commercialization of first-in-class oral therapies that address the neuromuscular dysfunction of obstructive sleep
